Although a randomized, double‐blind, multicenter, phase 3 trial conducted in 215 centers in 28 countries (IMmotion10) showed no significant prognostic improvement with adjuvant atezolizumab after RCC resection [33], a subanalysis indicated that high serum KIM‐1 levels were associated with improved clinical outcomes in patients administered adjuvant atezolizumab, which may indicate a relationship between KIM‐1 expression and immunogenicity in RCC [17]. This evidence concerns the gene HAVCR1 and renal cell adenocarcinoma.